Clinical Trials Logo

Aggressive Systemic Mastocytosis clinical trials

View clinical trials related to Aggressive Systemic Mastocytosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05219266 Available - Clinical trials for Acute Myeloid Leukemia

Managed Access Programs for PKC412, Midostaurin

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.

NCT ID: NCT04695431 Completed - Mast Cell Leukemia Clinical Trials

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Start date: December 2, 2020
Phase:
Study type: Observational

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

NCT ID: NCT03580655 Active, not recruiting - Mast Cell Leukemia Clinical Trials

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Start date: November 21, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

NCT ID: NCT02561988 Completed - Mast Cell Leukemia Clinical Trials

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Start date: March 10, 2016
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

NCT ID: NCT02415608 Terminated - Mast Cell Leukemia Clinical Trials

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01807598 Completed - Mast Cell Leukemia Clinical Trials

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them